🚀 VC round data is live in beta, check it out!
Cipla Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cipla and similar public comparables like BioMarin Pharmaceutical, RemeGen, Dr Reddy's Laboratories, Zydus Lifesciences and more.
Cipla Overview
About Cipla
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
Founded
1935
HQ
Employees
25.7K
Website
Sectors
Financials (LTM)
EV
$10B
Cipla Financials
Cipla reported last 12-month revenue of $3B and EBITDA of $647M.
In the same LTM period, Cipla generated $2B in gross profit, $647M in EBITDA, and $458M in net income.
Revenue (LTM)
Cipla P&L
In the most recent fiscal year, Cipla reported revenue of $3B and EBITDA of $845M.
Cipla expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $647M | XXX | $845M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 26% | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $458M | XXX | $618M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 19% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cipla Stock Performance
Cipla has current market cap of $11B, and enterprise value of $10B.
Market Cap Evolution
Cipla's stock price is $13.31.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10B | $11B | 1.0% | XXX | XXX | XXX | $0.76 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCipla Valuation Multiples
Cipla trades at 3.2x EV/Revenue multiple, and 14.9x EV/EBITDA.
EV / Revenue (LTM)
Cipla Financial Valuation Multiples
As of April 18, 2026, Cipla has market cap of $11B and EV of $10B.
Equity research analysts estimate Cipla's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cipla has a P/E ratio of 23.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11B | XXX | $11B | XXX | XXX | XXX |
| EV (current) | $10B | XXX | $10B | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | 14.9x | XXX | 11.4x | XXX | XXX | XXX |
| EV/EBIT | 18.4x | XXX | 13.7x | XXX | XXX | XXX |
| EV/Gross Profit | 4.9x | XXX | 5.2x | XXX | XXX | XXX |
| P/E | 23.5x | XXX | 17.4x | XXX | XXX | XXX |
| EV/FCF | 29.9x | XXX | 25.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cipla Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cipla Margins & Growth Rates
Cipla's revenue in the last 12 month grew by 9%.
Cipla's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Cipla's rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cipla's rule of X is 40% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Cipla Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | (6%) | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | (24%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 5% | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 37% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cipla Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cipla | XXX | XXX | XXX | XXX | XXX | XXX |
| BioMarin Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| RemeGen | XXX | XXX | XXX | XXX | XXX | XXX |
| Dr Reddy's Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Zydus Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Exelixis | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cipla M&A Activity
Cipla acquired XXX companies to date.
Last acquisition by Cipla was on XXXXXXXX, XXXXX. Cipla acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cipla
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCipla Investment Activity
Cipla invested in XXX companies to date.
Cipla made its latest investment on XXXXXXXX, XXXXX. Cipla invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cipla
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cipla
| When was Cipla founded? | Cipla was founded in 1935. |
| Where is Cipla headquartered? | Cipla is headquartered in India. |
| How many employees does Cipla have? | As of today, Cipla has over 25K employees. |
| Who is the CEO of Cipla? | Cipla's CEO is Umang Vohra. |
| Is Cipla publicly listed? | Yes, Cipla is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Cipla? | Cipla trades under CIPLA ticker. |
| When did Cipla go public? | Cipla went public in 1995. |
| Who are competitors of Cipla? | Cipla main competitors are BioMarin Pharmaceutical, RemeGen, Dr Reddy's Laboratories, Zydus Lifesciences. |
| What is the current market cap of Cipla? | Cipla's current market cap is $11B. |
| What is the current revenue of Cipla? | Cipla's last 12 months revenue is $3B. |
| What is the current revenue growth of Cipla? | Cipla revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Cipla? | Current revenue multiple of Cipla is 3.2x. |
| Is Cipla profitable? | Yes, Cipla is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cipla? | Cipla's last 12 months EBITDA is $647M. |
| What is Cipla's EBITDA margin? | Cipla's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Cipla? | Current EBITDA multiple of Cipla is 14.9x. |
| What is the current FCF of Cipla? | Cipla's last 12 months FCF is $323M. |
| What is Cipla's FCF margin? | Cipla's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Cipla? | Current FCF multiple of Cipla is 29.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.